InnovAge Holding (INNV) concentration risks

InnovAge's concentration is close to total and mostly structural. The company receives nearly all of its revenue through the PACE program, a high-share exposure: the business model, reimbursement framework and regulatory oversight all hinge on a single program design, so any change in PACE economics or rules would reach essentially the whole revenue base. Within that, payor concentration compounds the picture. A majority of capitation revenue is derived from a limited number of government payors, particularly Medicare and Medicaid, a medium-share dependency. Those payors set the rates and the rules, so the company has little pricing leverage and is exposed to budget and policy shifts. Geography adds a further layer. The payor relationships are concentrated in Colorado and California, a medium-share structural exposure, meaning state-level rate-setting, audit or administrative actions in just two markets can move results. Netting these out, the three exposures are not independent: they are nested views of one government-funded revenue stream. The program-level exposure sets the baseline, while the payor and state concentrations determine how sharply a policy or rate change in a specific jurisdiction could affect the verdict. None is offset by diversification elsewhere in the filing.

For the engine’s reasoning on INNV’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.